The Blank Page Is the Expensive Part

You can argue with a person about whether a tool is safe for a year, and get nowhere, because you are asking them to trust a claim about their own most accountable work. Or you can show them a real draft of that work, in the room, and change their mind in an afternoon. One of these is how most AI stalls resolve. The other is how they actually resolve.

Twelve months of no

A clinical-stage biotech had a wall coming: a stack of INDs and BLAs to file that ran well past what its regulatory writing team could physically reach. The executive team wanted regulatory to trial AI for first drafts. Regulatory said no. Not once, and not briefly. For twelve months.

The resistance was not stupidity. A writing team that owns some of the highest-stakes documents in the company was being asked to trust a new tool with exactly the work it is most accountable for. Caution there is a feature. But caution and a filing wall do not resolve themselves, and for a year they did not. It took a member of executive leadership to step in and mandate a trial. Notice where the change started: not with the team’s consent, but with Permission, used deliberately, because the stall had become more dangerous than the risk everyone was worried about.

Three days in a room

The company had also signed a six-figure vendor trial. Alongside it, we ran a head to head. I sat in a room for three days with my AI Product Partner and our standard, already-paid-for tools, and we drafted real first-draft sections of an upcoming IND. Not a demo document. Real sections the team would not otherwise have reached for months, buried under the backlog.

Two things came out of that room. Our drafts, produced with no six-figure vendor, were far better than what the paid trial produced. And several members of the writing team were dumbfounded, watching a real draft of their own work appear. The drafts were roughly 60 to 75 percent of the way to a usable first draft. That is not the number that matters. The number that matters is that it is not zero.

The aha

A blank page is the most expensive thing in regulatory writing. It is where the backlog lives. Handing a writer a section already 60 to 75 percent of the way there does not replace them. It starts them far past the hardest part and gives them their time back for the judgment that actually needs a human. The team saw that, in their own document, in real time, and after twelve months of no the aha arrived in an afternoon. The momentum did not come from the mandate. The mandate only bought the demonstration a chance to happen. A regulatory writer watching a real draft of their own work appear is worth more than any number of assurances that the tool is safe.

Be precise about what it was, because in regulated work the precision is the whole point. No AI-generated text went to the FDA. The first drafts were framing and a running start on structure. Then the team did the hard work themselves: the sourcing, the argument, the precision, the review. The author of record was human from start to finish. What the tool removed was the busywork at the front of the job. What it never touched was the work that reaches a regulator.

What does not transfer

Copy the lesson, not the setup. The trial only happened because an executive spent real capital to force it after a year of stall; without that Permission, the wall just gets closer. The six-figure vendor was not the villain, but it was the wrong first move: the capability was already inside tools the company owned, and nobody had tested that baseline before signing the check, which is the whole point of asking whether to self-serve before you buy. And a 60-to-75-percent draft is a starting point, not a submission. AI-drafted regulatory content has to go through your full human writing, review, and quality process, and what that must include is a question for your own quality and regulatory function, not a case study. The win was escaping the blank page. It was never skipping the work. The full record of the engagement is here.

Monday morning

Find the workflow drowning in backlog, the one where everyone can see the wall. Before you sign a large vendor trial, run a real head to head with the tools you already own, on a real document, with someone credible in the room. Keep humans as the authors of record and route every draft through your normal process. Then let the demonstration do what months of argument could not.

Cheers,
-Titus